Featured Article Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies June 9, 2021 | Featured, Press Releases Read More Recent articles Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies June 9, 2021 | Featured, Press Releases Read More SHORELINE BIOSCIENCES APPOINTS KIMBERLY MANHARD TO BOARD OF DIRECTORS May 19, 2021 | Press Releases Read More Shoreline Biosciences Appoints Vanessa L. Jacoby as Chief Financial Officer May 3, 2021 | Press Releases Read More Shoreline Biosciences Appoints Co-Founder William Sandborn, M.D. as Chief Medical Officer April 26, 2021 | Press Releases Read More Shoreline Biosciences Announces $43m Financing to Advance Pipeline of Allogeneic Natural Killer and Macrophage Cellular Immunotherapies Derived from Pluripotent Stem Cells April 7, 2021 | Press Releases Read More [Video]Working with Natural Born Killers: Using Natural Killer Cells to Improve Cancer Immunotherapies November 14, 2020 | Natural Killer Cells Read More
